GEM 231

Montefiore Medical Center · Phase 1 active Small molecule

At a glance

Generic name	GEM 231
Sponsor	Montefiore Medical Center
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors (PHASE1)
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GEM 231 CI brief — competitive landscape report
GEM 231 updates RSS · CI watch RSS
Montefiore Medical Center portfolio CI